This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The sprawling conglomerate — which owns a major health insurance company, physician practices, a pharmacy benefit manager, and numerous other firms — acquired or created more than 250 subsidiaries in 2024. UnitedHealth Group, the largest health care company in the U.S., has clear ambitions of getting bigger.
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database.
According to a 2024 study in Animals, gabapentin is also safe and well-tolerated for dogs with behavior disorders. Toxicity depends on multiple things, such as the dose ingested, the dogs size, and overall health, adds Dr. Nita Vasudevan, DVM, a veterinarian and veterinary consultant for Embrace Pet Insurance.
On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. First, the access landscape for 220 originator medicines approved by the EMA between 2021–2024 was assessed. Reimbursement status for each brand per European market was analysed during this period.
Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence.
1 Howard’s team built their telehealth service in collaboration with hospitals and health systems, especially to tackle the issue of hospital readmissions for Medicare and Medicaid patients—each of which can cost hospitals thousands of dollars.
The most common concerns include the following 1,3-5 : • Cost and insurance barriers: Affordability remains a major barrier, as patients have difficulty accessing CGMs due to high out-of-pocket costs or limited insurance coverage. Subscribe Now!
New Hope: Finerenone and the FINEARTS-HF Trial The 2024 release of the FINEARTS-HF (NCT04435626) trial data has renewed attention on finerenone, which has shown promise in patients with mildly reduced or pEF. Unlike the steroidal MRAs spironolactone and eplerenone, finerenone is nonsteroidal and may offer better tolerability and adherence.
SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization. The research also demonstrated that no patients were hospitalized to treat their inflammatory condition during the study period.
Personalized drug selection can lead to faster symptom control, fewer hospitalizations, and improved adherence—all of which contribute to better outcomes and a more streamlined care process. billion in July 2024. Real-World Evidence, Emerging Therapies, and Demonstrating Value Technological advances are accelerating this progress.
The financial conditions outlined in the extended agreement covering the three new ADC projects remain consistent with those specified in the original agreement signed in January 2024 for the initial three projects. In September 2024, Orion entered a partnership with Aitia to leverage AI in drug discovery and simulation in the oncology field.
Centers for Disease Control and Prevention (CDC), 2024) The state with the highest opioid dispensing rate in 2023 was Arkansas, with about 72 opioid prescriptions given per 100 people. CDC, 2024) There were more than 125 million opioid prescriptions given to Americans in 2023, a number that’s slowly been decreasing since 2019. (
In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
Only 4% of global drugs sales will have patent protection, compared to 12% and 6% in 2022 and 2024. Keytruda, approved to treat a range of solid tumours, was the top selling drug in the world in 2024, netting over $29bn in annual sales. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
That means that pharmacists in the twilight of their career have, at some point, filled a prescription, engaged in drug utilization review, filed insurance claims, and counseled per the Omnibus Budget Reconciliation Act of 1990 regulations for many of the products now found in front of the counter. Consumer Healthcare Products Association.
In June 2024, the company opened a new facility at the same site, which has already begun producing high-quality prefillable glass syringes. By GlobalData Learn more about Strategic Intelligence SCHOTT Pharma CEO Andreas Reisse stated: “To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields.
in April 2024 amidst plans to introduce regular incremental fee increases going forwards. Like all organisations, our operational costs have continued to increase due to larger utility bills, supplier costs and National Insurance contributions. ‘We Its fees increased by 7.5%
Madrigal accessed a large US market when it won accelerated US Food and Drug Administration (FDA) approval in March 2024 for the first MASH treatment in the region. in 2024, with $103.3m If approved in Europe, Rezdiffra would have the same indication. Don’t let policy changes catch you off guard. of that coming in Q4 alone.
The investment represents a substantial capital infusion to the $3.5bn announced in November 2024. AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). Give your business an edge with our leading industry insights.
The spray’s UK approval follows its launch in Spain in 2024 and in Germany last month. ALK signed an agreement with ARS for the exclusive licensing and commercialisation rights to EURneffy in the UK and EU last year. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
By GlobalData Learn more about Strategic Intelligence These concerns were made clear on 14 April 2024, when the European Parliament assigned its position of a baseline RDP at 7.5 Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Give your business an edge with our leading industry insights.
Indeed the $9.5bn in sales it generated in 2024, which includes revenue from a high-dose version, means it is one of the top-selling drugs in the world. Eylea’s glory days ending Alvotech is just the latest pharma company to spur an Eylea biosimilar into the European market after Bayer’s blockbuster lost regulatory exclusivity in mid-2024.
30, 2024 , TIRF manufacturers stopped production of these forms of medications. DEA, 2024) Fentanyl currently comes as an intravenous (IV) injection and a topical patch. Fentanyl lozenges, lollipops, sublingual tablets, and nasal sprays are no longer produced as of September 30, 2024. DEA, 2024) Another report found that U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content